

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/101525 A1

(51) International Patent Classification⁷: **C07D 215/26**, A61K 31/4704, A61P 11/06

(74) Agents: **HAGENAHL, Jeffrey A. et al.**; THERAVANCE, INC, 901 Gateway Boulevard, South San Francisco, CA 94080 (US).

(21) International Application Number: PCT/US2004/014302

(22) International Filing Date: 7 May 2004 (07.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/468,810 8 May 2003 (08.05.2003) US

(71) Applicant (for all designated States except US): **THERAVANCE, INC.** [US/US]; 901 Gateway Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **AXT, Sabine** [US/US]; 674 Morse Avenue #D, Sunnyvale, CA 94085 (US). **STERGIADES, Ioanna** [US/US]; 1515 Sutter Street, Apt. 325, San Francisco, CA 94109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CRYSTALLINE FORM OF ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST



(57) Abstract: The invention provides crystalline solvate forms of a salt of a novel β 2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the solvate forms, formulations containing the pharmaceutical compositions, methods of using the solvate forms to treat diseases associated with β 2 adrenergic receptor activity, and processes useful for preparing such solvate forms.

WO 2004/101525 A1



Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

5

Crystalline Form of Aryl Aniline β_2 Adrenergic Receptor Agonist

10

Field of the Invention

15 The invention is directed to crystalline solvate forms of a salt of a β_2 adrenergic receptor agonist. The invention is also directed to pharmaceutical compositions comprising the solvate forms, formulations containing the pharmaceutical compositions, methods of using the solvate forms to treat diseases associated with β_2 adrenergic receptor activity, and processes useful for preparing such solvate forms.

20

Background of the Invention

β_2 Adrenergic receptor agonists are recognized as effective drugs for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (including chronic bronchitis and emphysema). β_2 Adrenergic receptor agonists are also 25 useful for treating pre-term labor, and are potentially useful for treating neurological disorders and cardiac disorders. Commonly assigned U.S. Patent Nos. 6,653,323 B2 and 6,670,376 B1 disclose the novel compound *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine,



30

as a potent β_2 adrenergic receptor agonist. Compound **1** is alternatively referenced by the chemical name 8-hydroxy-5-((*R*)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-ylamino)-phenyl]ethylamino}ethyl)-1*H*-quinolin-2-one. .

5 In order to purify and formulate medicinal compounds for use as therapeutic agents, it is advantageous to provide the compounds in crystalline form. No crystalline form of compound **1** or of a pharmaceutical salt thereof has been reported previously.

Summary of the Invention

The present invention provides crystalline *N*-{2-[4-(3-phenyl-4-10 methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride in solvate form. In one aspect, the solvate form is a crystalline water and isopropanol solvate (hereinafter Form A). In a second aspect, the solvate form is a crystalline water hydrate (hereinafter Form B). Forms A and B of the monohydrochloride salt of compound **1** have been characterized by x-ray powder 15 diffraction (XRPD), differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR), and by elemental analysis.

The invention also provides pharmaceutical compositions comprising Form A, Form B, or combinations thereof of the monohydrochloride salt of compound **1** and a pharmaceutically acceptable carrier. Further, the invention provides combinations 20 comprising Form A, Form B, or combinations thereof of the monohydrochloride salt of compound **1** and one or more other therapeutic agents and pharmaceutical compositions comprising such combinations.

In another aspect, the invention provides a method of treating a disease or condition associated with β_2 adrenergic receptor activity (e.g. a pulmonary disease, such 25 as asthma or chronic obstructive pulmonary disease, pre-term labor, a neurological disorder, a cardiac disorder, or inflammation) in a mammal, the method comprising administering to the mammal, a therapeutically effective amount of Form A, Form B, or combinations thereof of the monohydrochloride salt of compound **1**. The invention also provides a method of treatment comprising administering a combination of a 30 therapeutically effective amount of Form A, Form B, or combinations thereof of the monohydrochloride salt of compound **1** together with one or more other therapeutic agents.

The invention further provides the monohydrochloride salt of compound **1** in crystalline solvate form for use in medical therapy, as well as the use of the monohydrochloride salt of compound **1** in crystalline solvate form or of a pharmaceutical composition comprising the monohydrochloride salt of compound **1** in crystalline solvate 5 form in the manufacture of a medicament for treating a disease or condition associated with β_2 adrenergic receptor activity in a mammal.

In a first synthetic method aspect, the invention provides a method of preparing Form A, the method comprising suspending a hydrochloride salt of compound **1** in a polar solvent comprising isopropanol and water, heating the suspension to between about 40 °C 10 and about 60 °C, and cooling the suspension to room temperature, resulting in the formation of Form A. In a second method aspect, the invention provides a method of preparing Form A from the free base of compound **1**.

The invention further provides a method of preparing Form B, the method comprising forming a first water slurry of Form A material, isolating a solid material from 15 the first water slurry, and forming a second water slurry from the isolated solid material, from which the hydrate Form B is obtained.

In yet another method aspect, this invention provides a method of reducing the amount of palladium in a composition comprising the diarylamine compound *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-20 quinolinon-5-yl)ethylamine, an intermediate in the synthesis of compound **1**, and palladium. The method comprises (a) contacting a solution comprising the diarylamine compound wherein each nitrogen atom has been protonated with an acid, palladium, and a solvent, with a functionalized solid support comprising (1-thioureido)alkyl or (mercapto)alkyl groups; and (b) separating the resulting solution from the solid support to 25 provide a composition having a reduced amount of palladium, wherein the solvent is compatible with the functionalized solid support.

Brief Description of the Drawings

The invention is illustrated by reference to the accompanying drawings.

30 FIG. 1 shows an x-ray powder diffraction pattern of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride water/isopropanol solvate (Form A).

FIG. 2 shows a differential scanning calorimetry trace (top trace, right side scale) and thermogravimetric trace (bottom trace, left side scale) of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride water/isopropanol solvate (Form A).

5 FIG. 3 shows an x-ray powder diffraction pattern of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride hydrate (Form B).

10 FIG. 4 shows a differential scanning calorimetry trace (top trace, right side scale) and thermogravimetric trace (bottom trace, left side scale) of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride hydrate (Form B).

Detailed Description of the Invention

When describing the compounds, compositions and methods of the invention, the
15 following terms have the following meanings, unless otherwise indicated.

The term "therapeutically effective amount" refers to an amount sufficient to effect treatment when administered to a patient in need of treatment.

The term "treatment" as used herein refers to the treatment of a disease or medical condition in a patient, such as a mammal (particularly a human) which includes:

20 (a) preventing the disease or medical condition from occurring, i.e., prophylactic treatment of a patient;

(b) ameliorating the disease or medical condition, i.e., eliminating or causing regression of the disease or medical condition in a patient;

(c) suppressing the disease or medical condition, i.e., slowing or arresting the development of the disease or medical condition in a patient; or

25 (d) alleviating the symptoms of the disease or medical condition in a patient.

The phrase "disease or condition associated with β_2 adrenergic receptor activity" includes all disease states and/or conditions that are acknowledged now, or that are found in the future, to be associated with β_2 adrenergic receptor activity. Such disease states 30 include, but are not limited to, bronchoconstrictive or pulmonary diseases, such as asthma and chronic obstructive pulmonary disease (including chronic bronchitis and emphysema), as well as neurological disorders and cardiac disorders. β_2 Adrenergic receptor activity is also known to be associated with pre-term labor (see U.S. Patent No.

5,872,126) and some types of inflammation (see WO 99/30703 and U.S. Patent No. 5,290,815).

The present invention provides crystalline *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride in solvate form. In a first aspect, the solvate is a crystalline water and isopropanol solvate (Form A). Form A is characterized by an x-ray powder diffraction (XRPD) pattern having two or more diffraction peaks at 2 θ values selected from the group consisting of 13.12±0.2, 13.66±0.2, 15.56±0.2, 15.68±0.2, 17.39±0.2, 18.39±0.2, 19.32±0.2, 19.61±0.2, 20.42±0.2, 21.38±0.2, 21.72±0.2, 10 22.95±0.2, 23.50±0.2, 23.99±0.2, and 24.60±0.2. In particular, Form A of the present invention is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2 θ values selected from the group consisting of 19.61±0.2, 20.42±0.2, 21.38±0.2, 21.72±0.2, and 24.60±0.2.

As is well known in the field of x-ray powder diffraction, relative peak heights of 15 XRPD spectra are dependent on a number of factors having to do with sample preparation and instrument geometry, while peak positions are relatively insensitive to experimental details. Thus, the crystalline Form A of compound 1 is also characterized by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with those shown in FIG. 1.

20 Form A is further characterized by its infrared absorption spectrum which shows significant absorption bands at 626±1, 638±1, 643±1, 656±1, 698±1, 829±1, 1048±1, 1233±1, 1301±1, 1399±1, 1490±1, 1508±1, 1598±1, 1640±1, and in the range 3360-3480 cm⁻¹.

25 Form A of the present invention is yet further characterized by its differential scanning calorimetry trace which shows a broad endothermic feature between about 75 and 115 °C and a sharper endothermic feature between about 145 and about 165 °C, as illustrated in FIG. 2. Without being bound to any theory of action, comparison of the DSC trace with thermogravimetric analysis data supports the inference that the lower temperature feature is associated with loss of isopropanol and water. The comparison 30 also supports the interpretation that the higher temperature feature of the DSC trace may be associated with the onset of decomposition and/or loss of water or HCl, with significant decomposition initiating above 220 °C.

Form A has been demonstrated to be stable upon storage for four weeks at 25 °C and 60 % humidity in closed containers as evidenced by lack of increase in peaks associated with degradants in high pressure liquid chromatography (HPLC) results and by insignificant changes in DSC, TGA, and XRPD traces.

5 Solvate Form A contains between about 2 and about 4 % (by weight) water and between about 2 and about 4 % (by weight) isopropanol, which corresponds to between about 0.7 and 1.3 equivalents of water and between about 0.2 and about 0.4 equivalents of isopropanol per mole of compound **1** hydrochloride.

In a second aspect, the solvate form is a crystalline water hydrate (Form B).

10 Form B is characterized by an x-ray powder diffraction (XRPD) pattern having two or more diffraction peaks at 2θ values selected from the group consisting of 13.26±0.2, 13.72±0.2, 15.66±0.2, 15.87±0.2, 17.43±0.2, 18.54±0.2, 19.44±0.2, 19.70±0.2, 20.54±0.2, 21.54±0.2, 21.82±0.2, 23.08±0.2, 24.12±0.2, and 24.69±0.2. In particular, Form B of the present invention is characterized by an x-ray powder diffraction pattern 15 having two or more diffraction peaks at 2θ values selected from the group consisting of 20.54±0.2, 21.82±0.2, 23.08±0.2, 24.12±0.2, and 24.69±0.2.

Form B of compound **1** is also characterized by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with those shown in FIG. 3. Comparison of the x-ray powder diffraction patterns of Form A and Form B 20 shows the peaks of Form B are shifted to higher 2θ values by an average of about 0.12 degrees.


Form B is further characterized by its infrared absorption spectrum which shows significant absorption bands at 653±1, 698±1, 829±1, 1232±1, 1262±1, 1383±1, 1445±1, 1488±1, 1508±1, 1548±1, 1598±1, 1640±1, 2831±1, 3033±1, and 3388±1 cm⁻¹.

25 Form B of the present invention is yet further characterized by its differential scanning calorimetry trace exhibited in FIG. 4. The DSC trace of Form B shows a sharp endothermic feature at between about 150 and 170 °C. Comparison of the DSC traces of Form A and Form B shows that the higher temperature endothermic feature of Form B is observed at a somewhat higher temperature than the comparable feature of Form A.

30 Form B contains between about 2 % and about 7 % water which corresponds to between about 0.7 and about 2.5 equivalents of water per mole of compound **1** hydrochloride.

The active agent, *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (**1**), can be prepared from the benzyl protected intermediate *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**), which can be 5 synthesized from readily available starting materials as shown in the following Scheme and further described in the Examples below. It will be appreciated that while specific process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated.

Scheme



Intermediate **R**, 5-(2-bromo-1-oxy)ethyl-8-benzyloxy-2(1*H*)-quinolinone, can be prepared as described in EP 147 791 B and analogously to the process described in WO 95/25104 for the corresponding chloroketone, as given in Example 1 below. Intermediate **FF**, 5-(2-bromo-(*R*)-1-hydroxyethyl-8-benzyloxy-2(1*H*)-quinolinone, can be formed by the chiral reduction of intermediate **R** using a oxazaborolidine catalyst prepared *in situ* following a procedure described in Mathre et al. *J. Org. Chem.*, 1991, 56, 751-762. The protected intermediate **HH**, 5-(2-bromo-(*R*)-1-*tert*-butyldimethylsiloxyethyl-8-benzyloxy-2(1*H*)-quinolinone, can be formed by the addition of *tert*-, 10 butydimethylsilylchloride trifluoromethane sulfonate (TBSOTF) and lutidine to intermediate **FF**, dissolved in dimethylformamide (DMF).

Intermediate **JJ**, *N*-[2-(4-bromophenyl)ethyl]-(*R*)-2-*tert*-butyldimethylsiloxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine, is obtained as the solid hydrochloride salt by reaction of **HH** with 4-bromophenethylamine. Intermediate **JJ** is coupled, with 15 4-methoxy 3-phenylaniline hydrochloride in the presence of a catalyst comprising 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and tris(dibenzylideneacetone)dipalladium(0) to give the protected diarylamine intermediate **NN**, *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-*tert*-butyldimethylsilyl-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine. The TBS protecting group is removed from **NN**, dissolved in 20 tetrahydrofuran (THF), by addition of triethylamine trihydrofluoride (TREAT HF), giving intermediate **PP**, *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine.

The benzyl protecting group is removed from intermediate **PP** by catalytic hydrogenolysis, using palladium on activated carbon, with addition of concentrated 25 hydrochloric acid to provide an amorphous hydrochloride salt of active compound **1**, which can be further purified with decolorizing charcoal.

As described above, a palladium based catalyst was used in the coupling reaction to produce intermediate **PP**. As a result, the product, compound **1**, or intermediates thereto, can be contaminated with unacceptable levels of palladium impurities. It has now 30 been discovered that such palladium impurities can be removed from such intermediates, in particular, intermediate **PP**, using a functionalized solid support comprising (1-thioureido)alkyl or (mercapto)alkyl groups.

Intermediate **PP** is dissolved in a solvent compatible with the solid support, where a compatible solvent is one that does not affect the performance of the functionalized solid support. An amount of acid, preferably hydrochloric acid, sufficient to convert the basic nitrogens of the intermediate to protonated form is added. Between about 1.05 and 5 about 1.2 equivalents of HCl per basic nitrogen is a sufficient amount. The resulting solution is diluted further with solvent and a functionalized solid support comprising (1-thioureido)alkyl or 3-(mercapto)alkyl groups is added. Preferably the solid support is a silica gel comprising 3-(1-thioureido)propyl or (mercapto)propyl groups. Preferably between about 5 and about 15 % (by weight) of the functionalized silica gel is added. A 10 preferred solvent compatible with the functionalized silica gel is a mixture of dichloromethane and methanol.

The resulting solution is separated from the solid support and the product is isolated. For example, the solution is stirred at room temperature for several hours followed by filtration through filter paper. The remaining silica is washed with additional 15 solvent. Combined filtrates are washed with saturated aqueous sodium bicarbonate and brine. The organic solution is treated with anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to give the product.

Accordingly, in a method aspect, this invention provides a method of reducing the amount of palladium in a composition comprising the diarylamine compound *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine and palladium, the method comprising (a) contacting a solution comprising the diarylamine compound wherein each nitrogen atom has been protonated with an acid, palladium, and a solvent, with a functionalized solid support comprising (1-thioureido)alkyl or (mercapto)alkyl groups; and (b) separating the resulting 25 solution from the solid support to provide a composition having a reduced amount of palladium, wherein the solvent is compatible with the functionalized solid support. Preferably, in the above method, the acid is hydrochloric acid; the solvent comprises a mixture of dichloromethane and methanol, and the functionalized solid support is a silica gel comprising 3-(1-thioureido)propyl or 3-(mercapto)propyl groups.

30 The crystalline water and isopropanol solvate (Form A) of the present invention can be formed by suspending the amorphous hydrochloride salt of compound **1** in a polar solvent comprising isopropanol and water, heating the suspension with stirring at a temperature of between about 40 °C and about 60 °C, and allowing the suspension to cool

to room temperature, resulting in the crystalline product. Preferably, the polar solvent is between about 40 % and about 60 % isopropanol.

For example, Form A can be formed by suspending the amorphous hydrochloride salt of compound **1** in a 50 % water/isopropanol mixture, heating at a temperature of 5 about 50 °C with stirring for over an hour and allowing the suspension to cool to room temperature at least overnight. The crystalline product can be isolated by filtration and dried under vacuum.

Alternatively, the crystalline water and isopropanol solvate (Form A) can be formed from the free base by suspending compound **1** in an aqueous polar solvent 10 comprising isopropanol and water and a molar excess of hydrochloric acid. Preferably the solvent contains between about 1.5 and about 2.5 equivalents of HCl. A preferred solvent is about 50% isopropanol/aqueous medium. The suspension is heated with stirring at a temperature of between about 40 °C and about 60 °C, and allowed to cool to room temperature, resulting in the crystalline product, which can be isolated by filtration 15 and dried under vacuum. The product can be recrystallized by suspending in a polar solvent, preferably isopropanol and water, heating with stirring at a temperature of between about 45 °C and about 55 °C and allowing to cool to room temperature, resulting in solvate Form A, which can be isolated and dried as above.

The crystalline water hydrate Form B can be prepared from solvate Form A by 20 forming a water slurry of Form A material, stirring for an extended period, for example, about a day, filtering, and resuspending the filtered material in water and stirring for an additional extended period. The slurry is filtered and dried under vacuum to produce the hydrate Form B. As reported in Examples 8 and 12, analysis of residual solvent indicated a sample of Form B contained 0.2 % isopropanol by weight, as compared with a sample 25 of Form A, which contained 3.4 % isopropanol.

Pharmaceutical Compositions

The solvates of the present invention, Form A and Form B, are advantageously used to prepare pharmaceutical compositions formulated for administration by inhalation. 30 Inhalation is an effective means for delivering an agent directly to the respiratory tract. There are three general types of pharmaceutical inhalation devices: nebulizer inhalers, dry powder inhalers (DPI), and metered-dose inhalers (MDI). Conventional nebulizer devices produce a stream of high velocity air that causes a therapeutic agent to spray as a mist

which is carried into the patient's respiratory tract. The therapeutic agent is formulated in a liquid form such as a solution or a suspension of micronized particles of respirable size, where micronized is typically defined as having about 90 % or more of the particles with a diameter of less than about 10 μm . Suitable nebulizer devices are provided

5 commercially, for example, by PARI GmbH (Starnberg, Germany). Other nebulizer devices have been disclosed, for example, in U.S. Patent 6,123,068. The present solvates can be formulated for use in a conventional nebulizer device as an aqueous solution at a concentration of between about 0.05 $\mu\text{g}/\text{mL}$ and about 1 mg/mL of the free base active agent, compound 1.

10 DPI's typically administer a therapeutic agent in the form of a free flowing powder that can be dispersed in a patient's air-stream during inspiration. Alternative DPI devices which use an external energy source are also being developed. In order to achieve a free flowing powder, the therapeutic agent can be formulated with a suitable excipient (e.g., lactose). A dry powder formulation can be made, for example, by combining dry lactose

15 having a particle size between about 1 μm and 100 μm with micronized particles of Form A, Form B, or a combination thereof and dry blending. Alternatively, the agent can be formulated without excipients. The formulation is loaded into a dry powder dispenser, or into inhalation cartridges or capsules for use with a dry powder delivery device.

Examples of DPI delivery devices provided commercially include Diskhaler

20 (GlaxoSmithKline, Research Triangle Park, NC) (see, e.g., U.S. Patent No. 5,035,237); Diskus (GlaxoSmithKline) (see, e.g., U.S. Patent No. 6,378,519; Turbuhaler (AstraZeneca, Wilmington, DE) (see, e.g., U.S. Patent No. 4,524,769); and Rotahaler (GlaxoSmithKline) (see, e.g., U.S. Patent No. 4,353,365). Further examples of suitable

25 DPI devices are described in U.S. Patent Nos. 5,415,162, 5,239,993, and 5,715,810 and references therein.

MDI's typically discharge a measured amount of therapeutic agent using compressed propellant gas. Formulations for MDI administration include a solution or suspension of active ingredient in a liquefied propellant. While chlorofluorocarbons, such as CCl_3F , conventionally have been used as propellants, due to concerns regarding

30 adverse affects of such agents on the ozone layer, formulations using hydrofluoroalkanes (HFA), such as 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane, (HFA 227) have been developed. Additional components of HFA formulations for MDI administration include co-solvents, such as ethanol, pentane, or minor amounts

of water; and surfactants, such as sorbitan trioleate, oleic acid, lecithin, and glycerin. (See, for example, U.S. Patent No. 5,225,183, EP 0717987 A2, and WO 92/22286).

Thus, a suitable formulation for MDI administration can include from about 0.001 % to about 2 % by weight of Form A, Form B, or a combination thereof, from about 5 0 % to about 20 % by weight ethanol, and from about 0 % to about 5 % by weight surfactant, with the remainder being the HFA propellant. In one approach, to prepare the formulation, chilled or pressurized hydrofluoroalkane is added to a vial containing the present crystalline form, ethanol (if present) and the surfactant (if present). To prepare a suspension, the pharmaceutical salt is provided as micronized particles. The formulation 10 is loaded into an aerosol canister, which forms a portion of an MDI device. Examples of MDI devices developed specifically for use with HFA propellants are provided in U.S. Patent Nos. 6,006,745 and 6,143,227.

In an alternative preparation, a suspension formulation is prepared by spray drying a coating of surfactant on micronized particles of the present crystalline material. (See, 15 for example, WO 99/53901 and WO 00/61108). For additional examples of processes of preparing respirable particles, and formulations and devices suitable for inhalation dosing see U.S. Patent Nos. 6,268,533, 5,983,956, 5,874,063, and 6,221,398, and WO 99/55319 and WO 00/30614.

The present active agent, compound **1**, is useful as a β_2 adrenergic receptor agonist 20 and therefore is useful for treating medical diseases or conditions mediated by β_2 adrenergic receptors or associated with β_2 adrenergic receptor activity in a mammal, i.e. medical conditions which are ameliorated by treatment with a β_2 adrenergic receptor agonist. Such medical conditions include but are not limited to a pulmonary disease, such 25 as asthma or chronic obstructive pulmonary disease, pre-term labor, a neurological disorder, a cardiac disorder, or inflammation.

The present active agent, compound **1**, is effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, 30 the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

Suitable doses of the therapeutic agent for inhalation administration are in the general range of from about 0.05 μ g/day to about 1000 μ g/day, preferably from about 0.1 μ g/day to about 500 μ g/day.

A compound can be administered in a periodic dose: weekly, multiple times per 5 week, daily, or multiple doses per day. The treatment regimen may require administration over extended periods of time, for example, for several weeks or months, or the treatment regimen may require chronic administration. Suitable doses for oral administration are in the general range of from about 0.05 μ g/day to about 100 mg/day, preferably from about 0.5 μ g/day to about 1000 μ g/day.

10 The invention thus provides a method of treating a mammal having a disease or condition associated with β_2 adrenergic receptor activity, the method comprising administering to the mammal a therapeutically effective amount of the monohydrochloride salt of compound 1 in crystalline solvate form or of a pharmaceutical composition comprising the monohydrochloride salt of compound 1 in crystalline solvate 15 form.

The present active agent can also be co-administered with one or more other therapeutic agents. For example, the present agent can be administered in combination with one or more therapeutic agents selected from anti-inflammatory agents (e.g. corticosteroids and non-steroidal anti-inflammatory agents (NSAIDs), anticholinergic 20 agents (particularly muscarinic receptor antagonists), other β_2 adrenergic receptor agonists, antiinfective agents (e.g. antibiotics or antivirals) or antihistamines. The invention thus provides, in a further aspect, a combination comprising Form A, Form B, or a combination thereof together with one or more therapeutic agent, for example, an anti-inflammatory agent, an anticholinergic agent, another β_2 adrenergic receptor agonist, 25 an antiinfective agent or an antihistamine.

The other therapeutic agents can be used in the form of pharmaceutically acceptable salts or solvates. As appropriate, the other therapeutic agents can be used as optically pure stereoisomers.

Suitable anti-inflammatory agents include corticosteroids and NSAIDs. Suitable 30 corticosteroids which may be used in combination with the compounds of the invention are those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity. Examples include methyl prednisolone, prednisolone,

dexamethasone, fluticasone propionate, $6\alpha,9\alpha$ -difluoro- 17α -[(2-furanylcarbonyl)oxy]- 11β -hydroxy- 16α -methyl-3-oxo-androsta-1,4-diene- 17β -carbothioic acid *S*-fluoromethyl ester, $6\alpha,9\alpha$ -difluoro- 11β -hydroxy- 16α -methyl-3-oxo- 17α -propionyloxy-androsta-1,4-diene- 17β -carbothioic acid *S*-(2-oxo-tetrahydro-furan-3S-yl) ester, beclomethasone esters (e.g. the 17-propionate ester or the 17,21-dipropionate ester), budesonide, flunisolide, mometasone esters (e.g. the furoate ester), triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR-106541, and ST-126. Preferred corticosteroids include fluticasone propionate, $6\alpha,9\alpha$ -difluoro- 11β -hydroxy- 16α -methyl- 17α -[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene- 17β -carbothioic acid *S*-fluoromethyl ester and $6\alpha,9\alpha$ -difluoro- 17α -[(2-furanylcarbonyl)oxy]- 11β -hydroxy- 16α -methyl-3-oxo-androsta-1,4-diene- 17β -carbothioic acid *S*-fluoromethyl ester, more preferably $6\alpha,9\alpha$ -difluoro- 17α -[(2-furanylcarbonyl)oxy]- 11β -hydroxy- 16α -methyl-3-oxo-androsta-1,4-diene- 17β -carbothioic acid *S*-fluoromethyl ester.

Suitable NSAIDs include sodium cromoglycate; nedocromil sodium; phosphodiesterase (PDE) inhibitors (e.g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors); leukotriene antagonists (e.g. monteleukast); inhibitors of leukotriene synthesis; iNOS inhibitors; protease inhibitors, such as tryptase and elastase inhibitors; beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g. adenosine 2a agonists); cytokine antagonists (e.g. chemokine antagonists such as, an interleukin antibody (α IL antibody), specifically, an α IL-4 therapy, an α IL-13 therapy, or a combination thereof); or inhibitors of cytokine synthesis. Suitable other β_2 -adrenoreceptor agonists include salmeterol (e.g. as the xinafoate), salbutamol (e.g. as the sulphate or the free base), formoterol (e.g. as the fumarate), fenoterol or terbutaline and salts thereof.

Also of interest is use of the present active agent in combination with a phosphodiesterase 4 (PDE4) inhibitor or a mixed PDE3/PDE4 inhibitor. The PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors. Preferred compounds are *cis* 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylic acid, 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-one and *cis*-[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol].

Other compounds of interest include:

Compounds set out in U.S. patent 5,552,438 issued 03 September, 1996; this patent and the compounds it discloses are incorporated herein in full by reference. The compound of particular interest, which is disclosed in U.S. patent 5,552,438, is *cis*-4-5 cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid (also known as cilomalast) and its salts, esters, pro-drugs or physical forms;

AWD-12-281 from elbion (Hofgen, N. *et al.* 15th EFMC Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, Abst P.98; CAS reference No. 247584020-9); a 9-benzyladenine derivative nominated NCS-613 (INSERM); D-4418 from Chiroscience and 10 Schering-Plough; a benzodiazepine PDE4 inhibitor identified as CI-1018 (PD-168787) and attributed to Pfizer; a benzodioxole derivative disclosed by Kyowa Hakko in WO99/16766; K-34 from Kyowa Hakko; V-11294A from Napp (Landells, L.J. *et al.* Eur Resp J [Annu Cong Eur Resp Soc (Sept 19-23, Geneva) 1998] 1998, 12 (Suppl. 28): Abst P2393); roflumilast (CAS reference No 162401-32-3) and a pthalazinone (WO99/47505, 15 the disclosure of which is hereby incorporated by reference) from Byk-Gulden; Pumafentrine, (-)-p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide which is a mixed PDE3/PDE4 inhibitor which has been prepared and published on by Byk-Gulden, now Altana; arofylline under development by Almirall-Prodesfarma; VM554/UM565 from 20 Vernalis; or T-440 (Tanabe Seiyaku; Fuji, K. *et al.* J Pharmacol Exp Ther, 1998, 284(1): 162), and T2585.

Other possible PDE-4 and mixed PDE3/PDE4 inhibitors include those listed in WO01/13953, the disclosure of which is hereby incorporated by reference.

Suitable anticholinergic agents are those compounds that act as antagonists at the 25 muscarinic receptor, in particular those compounds which are antagonists of the M₁, M₂, or M₃ receptors, or of combinations thereof. Exemplary compounds include the alkaloids of the belladonna plants as illustrated by the likes of atropine, scopolamine, homatropine, hyoscyamine; these compounds are normally administered as a salt, being tertiary amines. These drugs, particularly the salt forms, are readily available from a number of 30 commercial sources or can be made or prepared from literature data via, to wit:

Atropine - CAS-51-55-8 or CAS-51-48-1 (anhydrous form), atropine sulfate - CAS-5908-99-6; atropine oxide - CAS-4438-22-6 or its HCl salt - CAS-4574-60-1 and methylatropine nitrate - CAS-52-88-0.

Homatropine - CAS-87-00-3, hydrobromide salt - CAS-51-56-9, methylbromide salt - CAS-80-49-9.

Hyoscyamine (*d, l*) - CAS-101-31-5, hydrobromide salt - CAS-306-03-6 and sulfate salt - CAS-6835-16-1.

5 Scopolamine - CAS-51-34-3, hydrobromide salt - CAS-6533-68-2, methylbromide salt- CAS-155-41-9.

Preferred anticholinergics include ipratropium (e.g. as the bromide), sold under the name Atrovent, oxitropium (e.g. as the bromide) and tiotropium (e.g. as the bromide) (CAS-139404-48-1). Also of interest are: methantheline (CAS-53-46-3), propantheline 10 bromide (CAS- 50-34-9), anisotropine methyl bromide or Valpin 50 (CAS- 80-50-2), clidinium bromide (Quarzan, CAS-3485-62-9), copyrrolate (Robinul), isopropamide iodide (CAS-71-81-8), mepenzolate bromide (U.S. patent 2,918,408), tridihexethyl chloride (Pathilone, CAS-4310-35-4), and hexocyclium methylsulfate (Tral, CAS-115-63-9). See also cyclopentolate hydrochloride (CAS-5870-29-1), tropicamide (CAS-1508-75-15 4), trihexyphenidyl hydrochloride (CAS-144-11-6), pirenzepine (CAS-29868-97-1), telenzepine (CAS-80880-90-9), AF-DX 116, or methoctramine, and the compounds disclosed in WO01/04118, the disclosure of which is hereby incorporated by reference.

Suitable antihistamines (also referred to as H₁-receptor antagonists) include any one or more of the numerous antagonists known which inhibit H₁-receptors, and are safe 20 for human use. All are reversible, competitive inhibitors of the interaction of histamine with H₁-receptors. The majority of these inhibitors, mostly first generation antagonists, are characterized, based on their core structures, as ethanolamines, ethylenediamines, and alkylamines. In addition, other first generation antihistamines include those which can be characterized as based on piperazine and phenothiazines. Second generation antagonists, 25 which are non-sedating, have a similar structure-activity relationship in that they retain the core ethylene group (the alkylamines) or mimic a tertiary amine group with piperazine or piperidine. Exemplary antagonists are as follows:

Ethanolamines: carbinoxamine maleate, clemastine fumarate, diphenylhydramine hydrochloride, and dimenhydrinate.

30 Ethylenediamines: pyrilamine amleate, tripelennamine HCl, and tripelennamine citrate.

Alkylamines: chlropheniramine and its salts such as the maleate salt, and acrivastine.

Piperazines: hydroxyzine HCl, hydroxyzine pamoate, cyclizine HCl, cyclizine lactate, meclizine HCl, and cetirizine HCl.

Piperidines: Astemizole, levocabastine HCl, loratadine or its descarboethoxy analogue, and terfenadine and fexofenadine hydrochloride or another pharmaceutically acceptable salt.

Azelastine hydrochloride is yet another H₁ receptor antagonist which may be used in combination with a crystalline solvate of the invention.

Examples of preferred anti-histamines include methapyrilene and loratadine.

The invention thus provides, in a further aspect, a combination comprising a crystalline solvate of the present invention and a corticosteroid. As used herein, a crystalline solvate of the present invention means a monohydrochloride salt of compound 1 in solvate Form A, Form B, or a combination of Form A and Form B. In particular aspects, the invention provides combinations comprising a crystalline solvate of the present invention and fluticasone propionate; a crystalline solvate of the present invention and 6 α ,9 α -difluoro-17 α -[(2-furanylcarbonyl)oxy]-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carbothioic acid S-fluoromethyl ester; and a crystalline solvate of the present invention and 6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl)ester.

The invention thus provides, in a further aspect, a combination comprising a crystalline solvate of the present invention and a PDE4 inhibitor.

The invention thus provides, in a further aspect, a combination comprising a crystalline solvate of the present invention and an anticholinergic agent.

The invention thus provides, in a further aspect, a combination comprising a crystalline solvate of the present invention and an antihistamine.

The invention thus provides, in a further aspect, a combination comprising a crystalline solvate of the present invention together with a PDE4 inhibitor and a corticosteroid.

The invention thus provides, in a further aspect, a combination comprising a crystalline solvate of the present invention together with an anticholinergic agent and a corticosteroid.

Accordingly, the pharmaceutical compositions of the invention can optionally comprise combinations of a crystalline solvate of the present invention with one or more other therapeutic agents, as described above.

The individual compounds of such combinations may be administered either 5 sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.

According to a further aspect, the invention provides a method of treating a disease or condition associated with β_2 adrenergic receptor activity in a mammal, 10 comprising administering to the mammal a therapeutically effective amount of a combination of a crystalline solvate of the present invention with one or more other therapeutic agents.

Further, the present solvates, potentially can be formulated for other forms of administration, such as oral or parenteral administration. The solvates can be admixed 15 with conventional pharmaceutical carriers and excipients and used in the form of powders, tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. Such pharmaceutical compositions will contain from about 0.05 to about 90% by weight of the active compound, and more generally from about 0.1 to about 30%. Additional suitable pharmaceutical carriers for formulation of the crystalline solvates of the present invention 20 can be found in *Remington: The Science and Practice of Pharmacy, 20th Edition*, Lippincott Williams & Wilkins, Philadelphia, PA, 2000.

The following non-limiting examples illustrate representative pharmaceutical compositions of the invention, where active ingredient is defined as *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine, compound 1 in crystalline solvate Form A, crystalline solvate Form B, or a combination of Form A and Form B.

Formulation Example A

This example illustrates the preparation of a representative pharmaceutical composition for oral administration of the crystalline monoHCl salt of this invention:

5	Ingredients	Quantity per tablet, (mg)
	Active Ingredient	1
	Lactose, spray-dried	148
	Magnesium stearate	2

10 The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Formulation Example B

This example illustrates the preparation of another representative pharmaceutical composition for oral administration of the crystalline monoHCl salt of this invention:

15	Ingredients	Quantity per tablet, (mg)
	Active Ingredient	1
	Cornstarch	50
20	Lactose	145
	Magnesium stearate	5

The above ingredients are mixed intimately and pressed into single scored tablets.

25 Formulation Example C

This example illustrates the preparation of a representative pharmaceutical composition for oral administration of the crystalline monoHCl salt of this invention.

An oral suspension is prepared having the following composition.

30	Ingredients	
	Active Ingredient	3 mg
	Fumaric acid	0.5 g
	Sodium chloride	2.0 g
35	Methyl paraben	0.1 g
	Granulated sugar	25.5 g
	Sorbitol (70% solution)	12.85 g
	Veegum K (Vanderbilt Co.)	1.0 g
	Flavoring	0.035 mL
40	Colorings	0.5 mg
	Distilled water	q.s. to 100 mL

Formulation Example D

This example illustrates the preparation of a representative pharmaceutical composition containing the crystalline monoHCl salt of this invention.

5 An injectable preparation buffered to a pH of 4 is prepared having the following composition:

Ingredients

	Active Ingredient	0.1 mg
10	Sodium Acetate Buffer Solution (0.4 M)	2.0 mL
	HCl (1N)	q.s. to pH 4
	Water (distilled, sterile)	q.s. to 20 mL

Formulation Example E

15 This example illustrates the preparation of a representative pharmaceutical composition for injection using the crystalline monoHCl salt of this invention.

A reconstituted solution is prepared by adding 20 mL of sterile water to 1 mg of the compound of this invention. Before use, the solution is then diluted with 200 mL of an intravenous fluid that is compatible with the active compound. Such fluids are chosen 20 from 5% dextrose solution, 0.9% sodium chloride, or a mixture of 5% dextrose and 0.9% sodium chloride. Other examples are lactated Ringer's injection, lactated Ringer's plus 5% dextrose injection, Normosol-M and 5% dextrose, Isolyte E, and acylated Ringer's injection.

25

Formulation Example F

This example illustrates the preparation of a representative pharmaceutical composition for topical application of the crystalline monoHCl salt of this invention.

30

Ingredients

grams

	Active ingredient	0.2-10
35	Span 60	2
	Tween 60	2
	Mineral oil	5
	Petrolatum	10
	Methyl paraben	0.15
	Propyl paraben	0.05
	BHA (butylated hydroxy anisole)	0.01
40	Water	q.s. to 100

All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.

5

Formulation Example G

This example illustrates the preparation of a representative pharmaceutical composition containing a compound of the invention.

An aqueous aerosol formulation for use in a nebulizer is prepared by dissolving 0.1 mg of the monoHCl salt of the invention in 1 mL of a 0.9 % sodium chloride solution 10 acidified with citric acid. The mixture is stirred and sonicated until the active salt is dissolved. The pH of the solution is adjusted to a value in the range of from 3 to 8 by the slow addition of NaOH.

Formulation Example H

15 This example illustrates the preparation of a dry powder formulation containing a the monoHCl salt of the invention for use in inhalation cartridges.

Inhalation cartridges are filled with a pharmaceutical composition having the following ingredients:

20	Ingredients	mg/cartridge
	Active ingredient	0.2
	Lactose	25
25	The active ingredient is micronized prior to blending with lactose. The contents of the cartridges are administered using a powder inhaler.	

Formulation Example I

This example illustrates the preparation of a dry powder formulation containing 30 the crystalline monoHCl salt of this invention for use in a dry powder inhalation device.

A pharmaceutical composition is prepared having a bulk formulation ratio of micronized active ingredient to lactose of 1:200. The composition is packed into a dry powder inhalation device capable of delivering between about 10 and about 100 µg of active drug ingredient per dose.

35

Formulation Example J

This example illustrates the preparation of a formulation containing the crystalline monoHCl salt of this invention for use in a metered dose inhaler.

A suspension containing 5 % active ingredient, 0.5 % lecithin, and 0.5 % trehalose 5 is prepared by dispersing 5 g of active compound as micronized particles with mean size less than 10 μm in a colloidal solution formed from 0.5 g of trehalose and 0.5 g of lecithin dissolved in 100 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 μm . The particles are loaded into canisters with pressurized 1,1,1,2-tetrafluoroethane.

10

Formulation Example K

This example illustrates the preparation of a formulation containing the crystalline monoHCl salt of this invention for use in a metered dose inhaler.

A suspension containing 5 % active ingredient and 0.1 % lecithin is prepared by 15 dispersing 10 g of active compound as micronized particles with mean size less than 10 μm in a solution formed from 0.2 g of lecithin dissolved in 200 mL of demineralized water. The suspension is spray dried and the resulting material is micronized to particles having a mean diameter less than 1.5 μm . The particles are loaded into canisters with pressurized 1,1,1,2,3,3,3-heptafluoro-n-propane.

20

The following exemplify the preparation of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(*1H*)-quinolinon-5-yl)ethylamine, compound 1; and preparation and characterization of crystalline Form A and crystalline Form B of the present invention.

25

Example 1: Synthesis of 5-(2-bromo-1-oxy)ethyl-8-benzyloxy-2(*1H*)-quinolinone (R)
a. Synthesis of 8-acetoxy-2(*1H*)-quinolinone (CC)

8-Hydroxyquinoline-N-oxide (160.0 g, 1.0 mol) and acetic anhydride (800 mL, 8.4 mol) were heated at 100 °C for 3 hours and then cooled in ice. The product was collected 30 on a Buchner funnel, washed with acetic anhydride (2x100mL) and dried under reduced pressure to give 8-acetoxy-2(*1H*)-quinolinone (CC) (144 g) as a tan solid.

b. Synthesis of 5-acetyl-8-hydroxy-2(1*H*)-quinolinone (**DD**)

A slurry of aluminum chloride (85.7 g, 640 mmol) in 1,2-dichloroethane (280 mL) was cooled in ice, and compound **CC** (56.8 g, 280 mmol) was added. The mixture was warmed to room temperature, and then heated at 85°C. After 30 minutes acetyl chloride 5 (1.5 mL, 21 mmol) was added and the mixture was heated an additional 60 minutes. The reaction mixture was then cooled and added to 1N HCl (3 L) at 0°C with stirring. After stirring for 2 hours, the solids were collected on a Buchner funnel, washed with water (3x250mL) and dried under reduced pressure. The crude product isolated from several batches (135 g) was combined and triturated with dichloromethane (4 L) for 6 hours. The 10 product was collected on a Buchner funnel and dried under reduced pressure to give 5-acetyl-8-hydroxy-2(1*H*)-quinolinone (**DD**) (121 g).

c. Synthesis of 5-acetyl-8-benzyloxy-2(1*H*)-quinolinone (**EE**)

To 5-acetyl-8-hydroxy-2-quinolone (37.7 g, 186 mmol) was added 15 dimethylformamide (200 mL) and potassium carbonate (34.5 g, 250 mmol) followed by benzyl bromide (31.8 g, 186 mmol). The mixture was stirred at room temperature for 2.25 hour and then poured into saturated sodium chloride (3.5 L) at 0°C and stirred well for 1 hour. The product was collected and dried on a Buchner funnel for 1hour, and the resulting solids were dissolved in dichloromethane (2 L) and dried over sodium sulfate. 20 The solution was filtered through a pad of Celite and washed with dichloromethane (5x200 mL). The combined filtrate was then concentrated to dryness and the resulting solids were triturated with ether (500 mL) for 2 hours. The product was collected on a Buchner funnel, washed with ether (2x250 mL) and dried under reduced pressure to give 5-acetyl-8-benzyloxy-2(1*H*)-quinolinone (**EE**) (44 g) as an off white powder.

25

d. Synthesis of 5-(2-bromo-1-oxy)ethyl-8-benzyloxy-2(1*H*)-quinolinone (**R**)

5-Acetyl-8-benzyloxy-2(1*H*)-quinolinone (**EE**) (20.0 g, 68.2 mmol) was dissolved in dichloromethane (200 mL) and cooled to 0°C. Boron trifluoride diethyl etherate (10.4 mL, 82.0 mmol) was added via syringe and the mixture was warmed to room 30 temperature to give a thick suspension. The suspension was heated at 45°C (oil bath) and a solution of bromine (11.5 g, 72.0 mmol) in dichloromethane (100 mL) was added over 40 minutes. The mixture was kept at 45°C for an additional 15 minutes and then cooled to room temperature. The mixture was concentrated under reduced pressure and then

triturated with 10% aqueous sodium carbonate (200 mL) for 1 hour. The solids were collected on a Buchner funnel, washed with water (4x100 mL) and dried under reduced pressure. The product of two runs was combined for purification. The crude product (52 g) was triturated with 50% methanol in chloroform (500 mL) for 1 hour. The product was 5 collected on a Buchner funnel and washed with 50% methanol in chloroform (2x50 mL) and methanol (2x50 mL). The solid was dried under reduced pressure to give 5-(2-bromo-1-oxy)ethyl-8-benzyloxy-2(1*H*)-quinolinone (**R**) (34.1 g) as an off white powder.

10 **Example 2: Synthesis of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (PP)**

a. Synthesis of 5-(2-bromo-(*R*)-1-hydroxyethyl-8-benzyloxy-2(1*H*)-quinolinone (**FF**)
(R)-(+)- α,α -Diphenylprolinol (30.0 g, 117 mmol) and trimethylboroxine (11.1 mL, 78 mmol) were combined in toluene (300 mL) and stirred at room temperature for 30 minutes. The mixture was placed in a 150°C oil bath and liquid was distilled off. 15 Toluene was added in 20 mL aliquots, and distillation was continued for 4 hours. A total of 300 mL toluene was added. The mixture was finally cooled to room temperature. A 500 μ L aliquot was evaporated to dryness, weighed (246 mg) to determine that the concentration of catalyst was 1.8 M.

5-(2-Bromo-1-oxy)ethyl-8-benzyloxy-2(1*H*)-quinolinone (**R**) (90.0 g, 243 mmol) 20 was placed under nitrogen, tetrahydrofuran (900 mL) was added followed by the catalyst from above (1.8 M in toluene, 15 mL, 27 mmol). The suspension was cooled to -10±5°C in an ice/isopropanol bath. Borane (1.0 M in THF, 294 mL, 294 mmol) was added over 4 hours. The reaction was stirred an additional 45 minutes at -10°C, then methanol (250 mL) was added slowly. The mixture was concentrated under vacuum. The residue 25 was dissolved in boiling acetonitrile (1.3 L), filtered while hot and cooled to room temperature. The crystals were filtered, washed with acetonitrile and dried under vacuum to give 5-(2-bromo-(*R*)-1-hydroxyethyl-8-benzyloxy-2(1*H*)-quinolinone (**FF**) (72.5g, 196 mmol, 81% yield, 95% ee, 95% pure by HPLC area ratio).

30 b. Synthesis of 5-(2-bromo-(*R*)-1-*tert*-butyldimethylsiloxy)ethyl-8-benzyloxy-2(1*H*)-quinolinone (**HH**)

Compound **FF** (70.2 g, 189 mmol) was treated with *N,N*-dimethylformamide (260 mL) and cooled in an ice bath under nitrogen. 2,6-Lutidine (40.3 g, 376 mmol) was

added over 5 minutes followed slowly by *tert*-butyldimethylsilyl trifluoromethanesulfonate (99.8 g, 378 mmol), keeping the temperature below 20°C. The mixture was allowed to warm to room temperature for 45 minutes. Methanol (45 mL) was added to the mixture dropwise over 10 minutes and the mixture was partitioned

5 between ethyl acetate/cyclohexane(1:1, 500 mL) and water/brine (1:1, 500mL). The organics were washed twice more with water/brine (1:1, 500 mL each). The combined organics were evaporated under reduced pressure to give a light yellow oil. Two separate portions of cyclohexane (400 mL) were added to the oil and distillation continued until a thick white slurry was formed. Cyclohexane (300 mL) was added to the slurry and the

10 resulting white crystals were filtered, washed with cyclohexane (300 mL) and dried under reduced pressure to give 5-(2-bromo-(*R*)-1-*tert*-butyldimethylsiloxy)ethyl-8-benzyloxy-2(1*H*)-quinolinone (**HH**) (75.4 g, 151 mmol, 80% yield, 98.6 % ee).

c. Synthesis of *N*-[2-(4-bromophenyl)ethyl}-(*R*)-2-*tert*-butyldimethylsiloxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**JJ**)

15 Compound **HH** (136.5 g, 279 mmol), 4-bromophenethylamine (123 g, 615 mmol) and dimethyl sulfoxide (180 mL) were mixed at room temperature under nitrogen. Another 40 mL of dimethyl sulfoxide was added. The mixture was heated to 85°C for 5 hours. The reaction was partitioned between ethyl acetate (1 L) and 10% aqueous acetic acid (500 mL). The organics were washed with 10% aqueous acetic acid (3x500 mL), then with 1N sodium hydroxide (3x500 mL). The last wash was filtered through Celite (100 g). The organic layer was concentrated to 300 mL and cyclohexane (2x500 mL) was added and the solution concentrated to 300 mL. Sufficient cyclohexane was added to form 1.8 L final volume which was filtered through Celite (50 g). A solution of HCl in 20 isopropanol, prepared by slowly adding concentrated HCl (23.5 mL) to isopropanol (180 mL) at 10°C (internal), was added to the crude product and the reaction mixture was stirred for 5 hours, washed with cyclohexane (2x500 mL) and dried under reduced pressure for 24 hours to give *N*-[2-(4-bromophenyl)ethyl}-(*R*)-2-*tert*-butyldimethylsiloxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**JJ**) hydrochloride (145 g, 80 mol %, 25 106 wt %, HPLC purity 97.9 %).

d. Synthesis of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-*tert*-butyldimethylsilyl-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**NN**)

To compound **JJ** hydrochloride (73.7 g, 114 mmol) and 4-methoxy-3-phenylaniline hydrochloride (32.4 g, 137 mmol), toluene (380 mL) was added with mild agitation for 5 minutes, followed by sodium *tert*-butoxide (49.3 g, 513 mmol) in portions over 1 minute, and finally 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (10.65 g, 17 mmol) and tris(dibenzylideneacetone)dipalladium(0) (5.22 g, 5.7 mmol). The resulting mixture was stirred and heated to 85-89°C (internal) for 2.5 hours. The solution was cooled to room temperature, water (400 mL) was added and the mixture was stirred for 5 minutes, 10 filtered through Celite (80 g), and partitioned with toluene (100 mL). The organic layer was collected and concentrated under reduced pressure in a 40°C bath to give *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-*tert*-butyldimethylsilyl-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**NN**) as a dark viscous oil.

15 e. Synthesis of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**)

Compound **NN** from the previous step was dissolved in 280 ml of THF. Triethylamine trihydrofluoride (27.6 g, 171 mmol) was added to the solution, an additional 20 mL of THF was used to rinse down residual reagent, and the reaction was 20 stirred at 25°C under nitrogen for 16 hours. The reaction mixture was concentrated under reduced pressure in a 25°C bath to give a dark viscous oil to which dichloromethane (400 mL) was added, followed by 1N aqueous NaOH (200 mL). The reaction mixture was stirred for 5 hours. The top layer was discarded and the organic layer was concentrated to a viscous oil.

25 The oil was dissolved in dichloromethane to give a total volume of 630 mL. A 60 mL aliquot was taken and concentrated to 30 mL. Toluene (60 mL) was added, followed by a mixture of concentrated hydrochloric acid (2.7 mL) and methanol (4.5 mL) to give a thick paste covered in a free-flowing liquid. The liquid was carefully removed and the paste washed with toluene (50 mL). The gum was partitioned between 30 dichloromethane (40 mL) and 1N aqueous sodium hydroxide (40 mL) and the organic solvents were removed under reduced pressure. The residue was purified chromatographically over silica using a gradient of 0-10% methanol in dichloromethane

to give *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**) (98.6 % pure by HPLC area ratio).

5 **Example 3: Purification of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**)**

To free the material produced by the process of Examples 1 and 2 of palladium, intermediate **PP** (0.5 g, 0.82 mmol, Pd level ~850 ppm by ICP) was dissolved in 1:1 dichloromethane:methanol (5 mL) and 4M hydrochloric acid in dioxane (0.445 mL, 1.78 mmol) was added. The resulting dark brown solution was diluted further with 10 dichloromethane (7.5 mL) and 3-(1-thioureido)propyl functionalized silica gel (0.05 g) was added (Sigma-Aldrich, St. Louis, MO). The suspension was stirred at room temperature for 20 h followed by filtration through filter paper. The remaining yellow silica was washed with a mixture of 5 mL of methanol and 30 mL of dichloromethane. Combined organic solutions were washed with saturated aqueous sodium bicarbonate 15 (50 mL) and brine (50 mL). The organic solution was treated with anhydrous sodium sulfate for 30 minutes, filtered and evaporated under reduced pressure to give *N*-{2-[4-(3-phenyl-4methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**) (~90% yield, Pd level by ICP 30ppm, purity 97.4% by HPLC area ratio).

20

Example 4: Synthesis of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1**) hydrochloride**

To compound **PP** from the previous step (2.1g, 3.43 mmol) was added under nitrogen 10% palladium on carbon (420 mg) followed by ethylene glycol (16 mL) and 25 concentrated hydrochloric acid (0.57 mL, 6.9 mmol). The suspension was stirred vigorously under 1 atmosphere of hydrogen for 5 h. The solids were filtered off and washed with ethylene glycol (5 mL). The filtrate was warmed to 50 °C and water (21 mL) was added over 5 minutes under stirring. A brown gum formed which broke up to an off-white solid under continued stirring at 50 °C for 40 min. The solid was filtered off, with 30 water (2x20 mL) and air dried to afford an amorphous hydrochloride salt of compound **1** (2.5 g containing 44.3% water, 74% yield)

To improve the purity of the title compound, (2.5 g, 4.8 mmol) was dissolved in methanol (25 mL) at 40°C. The dark blue solution was cooled to room temperature, decolorizing charcoal (Darco-KB, 2.5 g) was added and the suspension stirred at room

temperature overnight. Solids were filtered off over Celite (2.0 g), filter cake was washed with methanol (2x10 mL) and solvent was evaporated under reduced pressure to leave an amorphous hydrochloride salt of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (**1**) as a light gray solid (1.5 g).

Example 5: Crystallization of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1**) monohydrochloride water/isopropanol solvate (Form A)**

10 The product of Example 4 (1.0 g, 1.68 mmol) was suspended in 50% isopropanol/water (10 mL) and heated to 50 °C under stirring. The amorphous material does not completely dissolve before off-white crystals start to appear. After 90 min the heating bath was turned off and the suspension allowed to cool to room temperature over 16 h. The crystalline solid was collected by filtration and washed with 50%
15 isopropanol/water (10 mL) and isopropanol (3 mL). The filter cake was air-dried for one hour then dried under vacuum until the loss on drying was less than 7%. The loss on drying was determined by drying a small aliquot to completion at high temperature to determine the fraction of a solid sample due to volatile solvents. Crystallization yielded 803 mg of material that was 97.8% pure by HPLC area ratio. The material contained
20 3.2% water (analysis by the Karl Fischer method) and 3.6% isopropanol (analysis by ¹H NMR).

Example 6 Synthesis of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1**) hydrochloride**

25 To a solution of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**) prepared by the process of Examples 1 and 2 (4.0 g, 6.5 mmol) in tetrahydrofuran (100 mL) and water (16 mL) was added 10% palladium on carbon (800 mg). The reaction was stirred vigorously under one atmosphere of hydrogen for 6.5 h. The solids were filtered off and washed with
30 tetrahydrofuran (4x25 mL) and then 50% methanol/tetrahydrofuran (2x25 mL). The combined filtrates were evaporated to dryness and the crude product was purified by reverse-phase HPLC. Fractions containing pure product were combined and lyophilized. The product from several runs was combined to give 4.68 g which was dissolved in acetonitrile (200 mL) and water (200 mL). 1.0 N HCl (18.7 mL) was added, and the

solution was lyophilized. The residue was again dissolved in acetonitrile (125 mL) and water (125 mL). 1.0 N HCl was added and the solution was lyophilized to give an amorphous hydrochloride salt of compound 1 as an off white powder. ¹H NMR (300MHz, DMSO-*d*6) δ 10.55 (br s, 1H), 9.40 (br s, 1H), 8.80, (br s, 1H), 8.26 (d, 1H), 7.60, (br s, 2H) 7.25-7.45 (m, 5H), 6.92-7.16 (m 10H), 6.55 (d, 1H), 5.45 (d, 1H), 3.69 (s, 3H) 2.80-3.15 (m, 6H); *m/z*: [M + H⁺] calcd for C₃₂H₃₁N₃O₄ 522.24; found 522.4.

10 **Example 7: Crystallization of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1) monohydrochloride water/isopropanol solvate (Form A)**

The product of Example 6 was taken up in 10 mL/g of 50% isopropanol/water and warmed to 50 °C under stirring. After 2 h the bath was removed and the suspension allowed to cool to room temperature over several hours. An additional 10 mL/g of 50% isopropanol/water was added and the heating cycle repeated. After 2 h the suspension 15 was allowed to cool slowly overnight by turning off the heating bath. The solid product was isolated by filtration and dried as described in Example 5.

20 **Example 8: Characterization of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1) monohydrochloride water/isopropanol solvate (Form A)**

The x-ray powder diffraction pattern and differential scanning calorimetry and thermogravimetric analysis traces of a lot of Form A material produced by the process of Example 7 are shown in FIGS. 1 and 2 respectively. The material was further characterized as follows: ¹H NMR (300MHz, DMSO-*d*6) δ 10.55 (br s, 1H), 9.40 (br s, 1H), 8.80, (br s, 1H), 8.26 (d, 1H), 7.60, (br s, 2H) 7.25-7.45 (m, 5H), 6.92-7.16 (m 10H), 25 6.55 (d, 1H), 5.45 (d, 1H), 3.69 (s, 3H) 2.80-3.15 (m, 6H); *m/z*: [M + H⁺] calcd for C₃₂H₃₁N₃O₄ 522.24; found 522.4. IR: 626, 638, 643, 698, 829, 1048, 1233, 1261, 1301, 1399, 1490, 1508, 1598, 1640, and in the range 3360-3480 cm⁻¹. Water content: 3.44%. Residual solvent by headspace GC: 3.42% isopropanol. Elemental analysis (wt%) calculated for C₃₂H₃₂N₃O₄Cl incl. 3.4% (1.15 mol) H₂O and 3.4% (0.33 mol) isopropanol: 30 C, 66.14; H, 6.22; N, 7.01; Cl, 5.92. Found: C, 66.57; H, 6.16; N, 6.99; Cl, 6.16.

Example 9: Preparation of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1)

The free base form of compound 1 was prepared from the protected intermediate **PP**. To a solution of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine (**PP**) prepared by the process of Examples 1 and 2 (43.0 g, 70 mmol) in 50% dichloromethane/methanol (200 mL) was added 20% palladium on carbon (8.6 g). The reaction was stirred vigorously under one atmosphere of hydrogen for 18 h. The solids were filtered off over Celite and washed with 50% dichloromethane/methanol (4x25 mL). The combined filtrates were 10 evaporated to dryness to give compound 1 (38 g, purity 92% by HPLC ratio) as a gray solid.

Example 10: Crystallization of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1) monohydrochloride water/isopropanol solvate (Form A)

15 Compound 1 (0.5 g) was suspended in a mixture of 2.5 mL isopropanol, 0.5 mL water and 2.0 mL 1N HCl (2.0 eq) (amounting to a mix of 5 mL 50% isopropanol/aqueous medium at a concentration of 10 mL/g). The suspension was warmed to 50 °C under stirring. After ~70% of starting material had dissolved, off-white crystals started to precipitate. Stirring and heating was continued for 2 h while the 20 remaining starting material dissolved and more crystalline material formed. The heating bath was removed, the suspension allowed to cool to room temperature for 2 h and the solids were removed by filtration and dried (465 mg). A small sample was retained for analysis and the remaining material was recrystallized as follows.

The remaining solid material was suspended in 4.5 mL of 50% isopropanol/water. 25 The suspension was stirred and warmed to 50 °C for 2 h. After allowing to cool to room temperature overnight the suspension was filtered as described above. The filter cake was washed with 50% isopropanol/water (2 mL) and isopropanol (2 mL). After suction-drying for an hour the filter cake was dried under vacuum to give Form A as an off white solid (332 mg). XRPD analysis showed a crystalline solid.

30 **Example 11: Preparation of *N*-(2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl)-(R)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine (1) monohydrochloride water hydrate (Form B)**

The crystalline product of Example 5 (Form A) (8.5 g, 15.2 mmol, containing 3.8 % isopropanol by ¹H NMR was transferred to a 500 mL round bottomed flask

equipped with a overhead stirrer. Deionized water (250 mL)was added and the suspension was stirred at room temperature under medium stirring speed. Samples for analysis were filtered, washed with water and dried for 30 min before taking an NMR spectrum. After 18 h of slurring, the material contained 1.1% isopropanol. After 24 h of 5 stirring the suspension was filtered through a medium speed filter paper and the moist filter cake re-suspended in 250 mL of water. After another 18 h of stirring (42 h of total stirring time) the IPA level had dropped to 0.4% and after a total of 48 h ^1H NMR showed an IPA level of 0.3%. The slurry was filtered through medium speed filter paper and air-dried for 30 min. The still moist filter cake was transferred to a crystallizing dish, spread 10 thin and dried in a vacuum oven at room temp. under house vacuum. After 24 h of drying the water level was determined to be 6.5% (analysis by Karl Fischer method), and after 29 h the water level was 4.3 %. The process yielded 7.6 g of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(R)-2-hydroxy-2-(8-hydroxy-2(1H)-quinolinon-5-yl)ethylamine (1) monohydrochloride water hydrate (Form B) that was crystalline by 15 XRPD.

Example 12: Characterization of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(R)-2-hydroxy-2-(8-hydroxy-2(1H)-quinolinon-5-yl)ethylamine (1) monohydrochloride water hydrate (Form B)

20 The x-ray powder diffraction pattern and differential scanning calorimetry and thermogravimetric analysis traces of a lot of Form B material produced by the process of Example 11 are shown in FIGS. 3 and 4 respectively. The material was further characterized as follows: ^1H NMR (300MHz, DMSO-*d*6) δ 10.52 (br s, 1H), 8.23 (d, 1H), 7.95, (s, 2H) 7.46-7.27 (m, 5H), 6.92-7.16 (m 10H), 6.55 (d, 1H), 6.17 (bs, 1H), 5.43 (d, 1H), 3.70 (s, 3H) 2.90-3.15 (m, 6H); *m/z*: [M + H $^+$] calcd for C₃₂H₃₁N₃O₄ 522.24; found 25 522.3. IR: 653, 698, 829, 1232, 1262, 1383, 1445, 1488, 1508, 1548, 1598, 1640, 2831, 3033, 3388. Water content 5.4%. Residual solvent by headspace GC: 0.2% isopropanol.

30 **Example 13: Solid state stability testing of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(R)-2-hydroxy-2-(8-hydroxy-2(1H)-quinolinon-5-yl)ethylamine (1) monohydrochloride water/isopropanol solvate (Form A)**

Samples (20 and 80 mg each) of the Form A material produced by the process of Example 7 were stored at 25 °C and 60 % relative humidity and at 40 °C and 75% relative humidity in open containers and in closed containers. After four weeks, for the material

stored at 25 °C and 60 % relative humidity in closed containers, analysis by DSC and TGA showed no detectable differences, and analysis by HPLC showed no detectable chemical degradation. The material stored in open containers showed loss of isopropanol over the course of four weeks.

5

Analytical Methods

X-ray powder diffraction patterns were obtained with a Shimadzu 6000 diffractometer using Cu K α (40.0 kV, 35.0 mA) radiation. The analysis was performed with the goniometer running in continuous-scan mode of 2°/min with a step size of 0.02° 10 over a range of 4 to 45°. Samples were prepared on glass specimen holders as a thin layer of powdered material. The instruments was calibrated to a silicon metal standard.

Differential scanning calorimetry traces were obtained with a TA instruments model DSCQ10. Samples were placed in sealed aluminum pans for analysis with an empty pan serving as the reference. Samples were equilibrated at 30°C and heated at 5° C 15 per minute to a temperature of 300° C. The instrument was calibrated with an indium standard.

Thermogravimetric analysis was conducted using a TA instruments model Q50. Samples were weighed in aluminum pans and heated from 30°C to 300° C at a rate of 5 °C/min.

20 The IR spectrum was determined over the wave number (v) range 4000 to 675 cm⁻¹ using an Avatar 360 FT-IR spectrometer equipped with a Nicolet omnis sample attenuated total reflection (ATR) sample holder.

¹H NMR spectra were acquired on a 300 MHz Varian Gemini 2000 spectrometer at ambient temperature. Samples were dissolved in DMSO-*d*6 and chemical shifts were 25 reported on a TMS scale using residual DMSO protons (2.49 ppm) as reference. ¹³C NMR spectra were acquired on JEOL Eclipse⁺ 400 MHz spectrometer.

HPLC analysis was performed using reverse phase conditions and a gradient of 2% to 90% acetonitrile over 6 minutes. Solvents contain 0.1% trifluoroacetic acid. Column: Zorbax 2.1x 50mm, flow rate 0.5 mL/min, observed wavelength 214 nm.

30 Mass spectrometric identification was performed by an electrospray ionization method (ESMS) with a Perkin Elmer instrument (PE SCIEX API 150 EX).

Elemental percentages of carbon, hydrogen, and nitrogen were determined by combustion analysis. Percentage of chlorine was determined by titration.

Water content was determined by coulometric Karl Fischer titration using a Brinkman Metrohm Karl Fischer Model 831 coulometer.

Residual solvents were determined by gas chromatography (GC) with headspace sampling and Flame Ionization Detection (FID) using an Agilent 6890 GC, Agilent 7694
5 headspace sampler and a 30 cm x 0.53 mm x 3 μ m J&W DB-624 capillary column.

Palladium levels were determined by the technique of Inductively Coupled Plasma (ICP) spectroscopy, based on measurement of atomic line emission spectra produced by a radio frequency inductively coupled plasma, using a Perkin Elmer Optima 3100 DV instrument.

10 Chiral purity was determined by chiral HPLC: Samples were analyzed using isocratic conditions with a mobile phase of 100 % methanol buffered with 0.5 % each acetic acid and triethylamine. Column: Astec Chirobiotic V 4.6x250mm, flowrate 0.4 mL/min, observed wavelength: 220 nm.

15 While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the
20 objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. Additionally, all publications, patents, and patent documents cited hereinabove are incorporated by reference herein in full, as though individually incorporated by reference.

WHAT IS CLAIMED IS:

1. Crystalline *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine monohydrochloride in solvate 5 form.
2. The compound of Claim 1 wherein the solvate form is a water and isopropanol solvate.
- 10 3. The compound of Claim 2 which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2θ values selected from the group consisting of 13.12±0.2, 13.66±0.2, 15.56±0.2, 15.68±0.2, 17.39±0.2, 18.39±0.2, 19.32±0.2, 19.61±0.2, 20.42±0.2, 21.38±0.2, 21.72±0.2, 22.95±0.2, 23.50±0.2, 23.99±0.2, and 24.60±0.2.
- 15 4. The compound of Claim 2 which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2θ values selected from the group consisting of 19.61±0.2, 20.42±0.2, 21.38±0.2, 21.72±0.2, and 24.60±0.2.
- 20 5. The compound of Claim 2 which is characterized by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1.
- 25 6. The compound of Claim 2 having an infrared absorption spectrum with significant absorption bands at 626±1, 638±1, 643±1, 656±1, 698±1, 829±1, 1048±1, 1233±1, 1301±1, 1399±1, 1490±1, 1508±1, 1598±1, 1640±1, and in the range 3360-3480 cm⁻¹.
- 30 7. The compound of Claim 2 which is characterized by a differential scanning calorimetry trace substantially in accordance with the trace shown in FIG. 2.

8. The compound of Claim 2 wherein the compound comprises between about 2 % and about 4 % by weight water and between about 2 % and about 4 % by weight isopropanol.

5 9. The compound of Claim 1 wherein the solvate form is a water hydrate.

10. The compound of Claim 9 which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2 θ values selected from the group consisting of 13.26±0.2, 13.72±0.2, 15.66±0.2, 15.87±0.2, 17.43±0.2, 18.54±0.2, 10 19.44±0.2, 19.70±0.2, 20.54±0.2, 21.54±0.2, 21.82±0.2, 23.08±0.2, 24.12±0.2, and 24.69±0.2.

11. The compound of Claim 9 which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2 θ values selected from the 15 group consisting of 20.54±0.2, 21.82±0.2, 23.08±0.2, 24.12±0.2, and 24.69±0.2.

12. The compound of Claim 9 which is characterized by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 3.

20

13. The compound of Claim 9 having an infrared absorption spectrum with significant absorption bands at 653±1, 698±1, 829±1, 1232±1, 1262±1, 1383±1, 1445±1, 1488±1, 1508±1, 1548±1, 1598±1, 1640±1, 2831±1, 3033±1, and 3388±1 cm⁻¹.

25 14. The compound of Claim 9 which is characterized by a differential scanning calorimetry trace substantially in accordance with the trace shown in FIG. 4.

15. The compound of Claim 9 wherein the compound comprises between about 2 % and about 7 % by weight water.

30

16. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of Claims 1 to 15 and a pharmaceutically acceptable carrier.

17. The pharmaceutical composition of Claim 16, wherein the composition further comprises a therapeutically effective amount of one or more other therapeutic agents.

5

18. The pharmaceutical composition of Claim 16, wherein the composition is formulated for administration by inhalation.

19. A combination comprising the compound of any one of Claims 1 to 15 and 10 one or more other therapeutic agents.

20. The combination of Claim 19 wherein the other therapeutic agent is a corticosteroid, an anticholinergic agent, or a PDE4 inhibitor.

15 21. A combination comprising a compound of any one of Claims 1 to 15 and 6 α ,9 α -difluoro-17 α -[(2-furanylcarbonyl)oxy]-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carbothioic acid *S*-fluoromethyl ester or 6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy- androsta-1,4-diene-17 β -carbothioic acid *S*-(2-oxo-tetrahydro-furan-3S-yl) ester.

20

22. A compound as claimed in any one of Claims 1 to 15 for use in medical therapy.

23. The use of a compound as claimed in any one of Claims 1 to 15 in the 25 manufacture of a medicament for treating a disease or condition associated with β_2 adrenergic receptor activity in a mammal.

24. The use of claim 23 wherein the disease or condition is a pulmonary disease.

30

25. The use of claim 24 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.

26. A process for preparing the compound of Claim 2, the process comprising the steps of:

- (a) suspending *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine hydrochloride in a polar solvent comprising isopropanol and water;
- (b) heating the suspension to between about 40 °C and about 60 °C; and
- (c) cooling the suspension to room temperature, resulting in the formation of the compound of Claim 2.

10 27. A process for preparing the compound of Claim 2, the process comprising the steps of:

- (a) suspending *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine in a polar solvent comprising isopropanol, water, and a molar excess of hydrochloric acid;
- (b) heating the suspension to between about 40 °C and about 60 °C; and
- (c) cooling the suspension to room temperature, resulting in the formation of the compound of Claim 2.

20 28. A process for preparing the compound of Claim 9, the process comprising the steps of:

- (a) forming a first water slurry of crystalline *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine hydrochloride water and isopropanol solvate;
- (b) isolating a solid material from the first water slurry
- (c) forming a second water slurry from the isolated solid material from which the compound of Claim 9 is obtained.

29. A method of reducing the amount of palladium in a composition
30 comprising the diarylamine compound *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-benzyloxy-2(1*H*)-quinolinon-5-yl)ethylamine and palladium, the method comprising the steps of:

(a) contacting a solution comprising the diarylamine compound wherein each nitrogen atom in the diarylamine compound has been protonated with an acid, palladium, and a solvent, with a functionalized solid support comprising (1-thioureido)alkyl or (mercapto)alkyl groups; and

5 (b) separating the resulting solution from the solid support to provide a composition having a reduced amount of palladium;

wherein the solvent is compatible with the functionalized solid support.

30. The method of Claim 29 wherein the acid is hydrochloric acid, the solvent
10 comprises dichloromethane and methanol and the functionalized solid support is a functionalized silica gel comprising 3-(1-thioureido)propyl or 3-(mercapto)propyl groups.

31. A method of treating a disease or condition associated with β_2 adrenergic receptor activity in a mammal, the method comprising administering to the mammal, a
15 therapeutically effective amount of a compound of any one of Claims 1 to 15.

32. The method of Claim 31 wherein the disease or condition is a pulmonary disease.

20 33. The method of Claim 32 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.

34. The method of Claim 31 wherein the method further comprises administering a therapeutically effective amount of one or more other therapeutic agents.

25

35. The method of Claim 34 wherein the other therapeutic agent is a corticosteroid, an anticholinergic agent, or a PDE4 inhibitor.

30




FIG. 1




FIG. 2




FIG. 3




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/014302

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D215/26 A61K31/4704 A61P11/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 03/042164 A (NODWELL MATTHEW B ; AGGEN JAMES (US); JACOBSEN JOHN R (US); MORAN EDMUND J (US)) 22 May 2003 (2003-05-22) cited in the application example 6a example 6	1-28, 31-35
P, X	-----	29, 30
P, A	WO 03/042160 A (AGGEN JAMES ; JACOBSEN JOHN R (US); MORAN EDMUND J (US); THERAVANCE INC) 22 May 2003 (2003-05-22) cited in the application examples 8,9	1-28, 31-35
P, X	examples 8,9 -----	29, 30
A	WO 01/42193 A (ADVANCED MEDICINE INC ; CHOI SEOK KI (US); GRIFFIN JOHN H (US); MORAN) 14 June 2001 (2001-06-14) claims 1,16 -----	1-35
	-----	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 September 2004

23/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Wörth, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/014302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 894 219 A (BAKER STEPHEN P ET AL) 16 January 1990 (1990-01-16) claims 1,4 -----	1-35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/014302

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 31-35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/014302

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 03042164	A	22-05-2003	CA	2466962 A1	22-05-2003
			EP	1446379 A1	18-08-2004
			WO	03042160 A1	22-05-2003
			WO	03042164 A1	22-05-2003
			US	2003153597 A1	14-08-2003
			US	6670376 B1	30-12-2003
			US	2003229058 A1	11-12-2003
			US	2004059116 A1	25-03-2004
			US	2004063755 A1	01-04-2004
WO 03042160	A	22-05-2003	CA	2466962 A1	22-05-2003
			EP	1446379 A1	18-08-2004
			WO	03042160 A1	22-05-2003
			WO	03042164 A1	22-05-2003
			US	2003153597 A1	14-08-2003
			US	6670376 B1	30-12-2003
			US	2003229058 A1	11-12-2003
			US	2004059116 A1	25-03-2004
			US	2004063755 A1	01-04-2004
WO 0142193	A	14-06-2001	US	6576793 B1	10-06-2003
			AT	253039 T	15-11-2003
			AU	2254601 A	18-06-2001
			BR	0015962 A	30-07-2002
			CA	2391293 A1	14-06-2001
			CN	1402702 T	12-03-2003
			CZ	20021831 A3	13-11-2002
			DE	60006280 D1	04-12-2003
			DE	60006280 T2	29-07-2004
			DK	1235787 T3	08-03-2004
			EA	4263 B1	26-02-2004
			EP	1235787 A1	04-09-2002
			ES	2208453 T3	16-06-2004
			HU	0203638 A2	28-02-2003
			JP	2003516381 T	13-05-2003
			NO	20022655 A	05-06-2002
			PT	1235787 T	31-03-2004
			SI	1235787 T1	30-04-2004
			SK	9922002 A3	06-11-2002
			WO	0142193 A1	14-06-2001
			US	2003087307 A1	08-05-2003
US 4894219	A	16-01-1990	NONE		